PubMed Health⌕ Search
Home/Archive/PubMed

PubMed · 16462165

Small intestinal motility.

Michael P Jones·Sarah Wessinger
View original source ↗Export metadata ↓

Abstract

PURPOSE OF REVIEW: To review recently published studies presenting novel and relevant information on small intestinal motility in humans and animals. RECENT FINDINGS: Mechanisms of intestinal dysmotility in patients with pseudoobstruction and colonic inertia are becoming better clarified. The role of enteric flora in health and disease is an important and rapidly evolving area that will no doubt yield significant advances in the evaluation and treatment of many digestive disorders. The role of bacterial overgrowth in irritable bowel syndrome requires further study. The mechanisms underlying postoperative ileus are becoming both better understood and increasingly complex. Peripheral opioid antagonists may represent an important therapeutic advance in the treatment of ileus. Cannabinoids also appear to play a role in ileus and this echoes our rapidly evolving understanding of these compounds in the regulation of motility. SUMMARY: Small intestinal motility remains an understudied area. Recent publications have shed additional light on myogenic, neural, and hormonal control mechanisms.

Explore related subjects

Gastrointestinal MotilityHumansIntestinal Pseudo-ObstructionIntestine, SmallRisk FactorsJournal ArticleReview

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

Michael P Jones, Sarah Wessinger. 2006. Small intestinal motility.. https://doi.org/10.1097/01.mog.0000203867.33008.52

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed2006

Review article: intestinal serotonin signalling in irritable bowel syndrome.

Alterations in motility, secretion and visceral sensation are hallmarks of irritable bowel syndrome. As all of these aspects of gastrointestinal function involve serotonin signalling between enterochromaffin cells and sensory nerve fibres in the mucosal layer of the gut, potential alterations in mucosal serotonin signalling have been explored as a possible mechanism of altered function and sensation in irritable bowel syndrome. Literature related to intestinal serotonin signalling in normal and pathophysiological conditions has been searched and summarized. Elements of serotonin signalling that are altered in irritable bowel syndrome include: enterochromaffin cell numbers, serotonin content, tryptophan hydroxylase message levels, 5-hydroxyindoleacedic acid levels, serum serotonin levels and expression of the serotonin-selective reuptake transporter. Both genetic and epigenetic factors could contribute to decreased serotonin-selective reuptake transporter in irritable bowel syndrome. A serotonin-selective reuptake transporter gene promoter polymorphism may cause a genetic predisposition, and inflammatory mediators can induce serotonin-selective reuptake transporter downregulation. While a psychiatric co-morbidity exists with IBS, changes in mucosal serotonin handling support the concept that there is a gastrointestinal component to the aetiology of irritable bowel syndrome. Additional studies will be required to gain a more complete understanding of changes in serotonin signalling that are occurring, their cause and effect relationship, and which of these changes have pathophysiological consequences.

Gastrointestinal Motility↗
PubMed2006

Changing face of irritable bowel syndrome.

Recent years have witnessed tremendous progress in our understanding of irritable bowel syndrome (IBS). It is evident that this is a truly global disease associated with significant symptoms and impairments in personal and social functioning for afflicted individuals. Advances in our understanding of gut flora-mucosal interactions, the enteric nervous system and the brain-gut axis have led to substantial progress in the pathogenesis of symptoms in IBS and have provided some hints towards the basic etiology of this disorder, in some subpopulations, at the very least. We look forward to a time when therapy will be addressed to pathophysiology and perhaps, even to primary etiology. In the meantime, a model based on a primary role for intestinal inflammation serves to integrate the various strands, which contribute to the presentation of IBS.

Gastrointestinal Motility↗